.

Deeper Knowledge, Faster

  • Plan your formulary budget
  • Find suppliers and generic API sources
  • Set up watchlists for daily email updates

► See Plans & Pricing

Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving 500+ biopharmaceutical companies globally:

Healthtrust
Johnson and Johnson
Merck
UBS
Federal Trade Commission
Novartis
QuintilesIMS
Julphar
Cipla
AstraZeneca

Generated: June 28, 2017

DrugPatentWatch Database Preview

Finafloxacin - Generic Drug Details

« Back to Dashboard

What are the generic sources for finafloxacin and what is the scope of finafloxacin freedom to operate?

Finafloxacin
is the generic ingredient in one branded drug marketed by Novartis Pharms Corp and is included in one NDA. There are six patents protecting this compound. Additional information is available in the individual branded drug profile pages.

Finafloxacin has seventy-seven patent family members in thirty-five countries.

Summary for Generic Name: finafloxacin

Tradenames:1
Patents:6
Applicants:1
NDAs:1
Bulk Api Vendors: see list10
Clinical Trials: see list7
Patent Applications: see list9
Drug Prices:see low prices
DailyMed Link:finafloxacin at DailyMed
Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Novartis Pharms Corp
XTORO
finafloxacin
SUSPENSION/DROPS;OTIC206307-001Dec 17, 2014RXYesYes9,504,691► SubscribeY ► Subscribe
Novartis Pharms Corp
XTORO
finafloxacin
SUSPENSION/DROPS;OTIC206307-001Dec 17, 2014RXYesYes9,119,859► Subscribe ► Subscribe
Novartis Pharms Corp
XTORO
finafloxacin
SUSPENSION/DROPS;OTIC206307-001Dec 17, 2014RXYesYes6,432,948► SubscribeYY ► Subscribe
Novartis Pharms Corp
XTORO
finafloxacin
SUSPENSION/DROPS;OTIC206307-001Dec 17, 2014RXYesYes► Subscribe► Subscribe
Novartis Pharms Corp
XTORO
finafloxacin
SUSPENSION/DROPS;OTIC206307-001Dec 17, 2014RXYesYes8,536,167► Subscribe ► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Expired Orange Book Patents for Generic Ingredient: finafloxacin

Applicant Tradename Generic Name Dosage NDA Approval Date Patent No. Patent Expiration
Novartis Pharms Corp
XTORO
finafloxacin
SUSPENSION/DROPS;OTIC206307-001Dec 17, 20146,133,260► Subscribe
Novartis Pharms Corp
XTORO
finafloxacin
SUSPENSION/DROPS;OTIC206307-001Dec 17, 20146,432,948► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

International Patent Family for Ingredient: finafloxacin

Country Document Number Estimated Expiration
Norway325617► Subscribe
Hong Kong1025517► Subscribe
Slovakia14962000► Subscribe
World Intellectual Property Organization (WIPO)2011003091► Subscribe
Japan2015134827► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

The estimated expiration dates shown above are derived by simply adding 20 years to the priority date.
Due to the complexity of determining patent expirations even in a single country, compounded by the diversity of global patent laws, it is advisable to have patent counsel verify freedom to operate.

Export unavailable in trial.
Subscribe for complete access.

« Back to Dashboard

For more information try a trial or see the database preview and plans and pricing

Serving 500+ biopharmaceutical companies globally:

Teva
Fuji
Cipla
UBS
Federal Trade Commission
Deloitte
Moodys
US Army
Julphar
AstraZeneca

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

Copyright 2002-2017 thinkBiotech LLC
ISSN: 2162-2639

Secure SSL Encrypted

Follow DrugPatentWatch:



Google
Twitter
Google Plus
botpot